Navigation Links
Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
Date:5/15/2012

r Pharma

Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world. The Swiss affiliate is located in Villars-sur-Glâne (Canton Fribourg).

For more information about Vifor Pharma and its parent company Galenica, please visit http://www.viforpharma.com and http://www.galenica.com.

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Vifor Pharma Media Contact
Beatrix Benz
Head of Global Communications
Vifor Pharma Ltd.
Tel.: +41-58-851-80-00
Fax: +41-58-851-80-03
beatrix.benz@viforpharma.com

Debio R.P. Contact
Cédric Sager
CEO
Tel.: +41(0)27-721-79-00
Fax: +41(0)27-721-79-01
csager@debiopharm.ch    

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk
   


In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com
   



'/>"/>
SOURCE The Debiopharm Group and Vifor Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
2. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
3. Continuity as Debiopharm Group™ Management Moves Forward
4. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
5. Debiopharm Group™ and Aurigene Nominate Development Candidate
6. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
7. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
8. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
11. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 Pfenex ... its previously announced initial public offering of 8,333,333 shares of ... $6.00 per share. All of the common stock was offered ... 30-day option to purchase up to 1,250,000 additional shares of ... of common stock are traded on the NYSE MKT under ...
(Date:7/29/2014)... July 29, 2014  Covance Inc. (NYSE: ... ended June 30, 2014.  Net revenue was $639 million, ... On a GAAP basis, the company reported earnings of ... company reported pro forma earnings per diluted share of ... Pro forma results exclude asset impairment charges totaling $52.6 ...
(Date:7/29/2014)... , July, 29  2014 ISPE—the International ... hired John Bournas as President and ... plans to leave the Society last fall.  Mr. ... competencies in the healthcare association industry as well ... Society a clear vision for the expansion of ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3
(Date:7/29/2014)... VA (PRWEB) July 29, 2014 The ... members of the Deadliest Cancer Coalition, led advocacy efforts ... officials in the newly established Congressional Caucus on the Deadliest ... efforts, the caucus now features the following 20 members: , ... Eshoo (CA-18) – May 2, 2014, Rep. Zoe Lofgren (CA-19) ...
(Date:7/29/2014)... electroacupuncture (EA) a form of acupuncture where ... of acupuncture needles produces significant improvements in ... eight weeks for early stage breast cancer patients ... aromatase inhibitors (AIs) to treat breast cancer. The ... intervention led by researchers at the Perelman School ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Cure for ... any sufferer who is looking for an all-natural holistic cure ... new program, Sarah Summer, says that her method is 100 ... too. Actually, this is the reason why she was so ... The Natural Cure for Yeast Infection review indicates ...
(Date:7/29/2014)... July 29, 2014 For numerous women from ... relationship work can turn out being quite hard. Well, the ... he discovered the method that can help all these women. ... make a guy show love and attention every day. ... method was actually created by Alex Carter who published a ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2
... is not an option, survey finds, , TUESDAY, July 21 ... try to buy an individual health insurance policy on their ... are just too expensive, according to a new study. , ... supports independent research on health policy reform, found that roughly ...
... ... better serve residents, families , ... Wausau, Wisc. (Vocus) July 21, 2009 -- My InnerView, the leading provider ... today announced the creation of the My SeniorCare Edvantage Program, an online health management ...
... LAWRENCE, Mass. , July 21 NxStage Medical, ... innovative dialysis products, today announced that its Medisystems subsidiary has ... Fenwal, Inc. of Lake Zurich, Ill. Medisystems provides needle ... focused on improving blood collection, separation, safety and availability for ...
... child welfare practices from across the country offer hope for America,s most ... SEATTLE, July 21 All across America, child welfare systems are ... improving the lives of children in foster care as well as children ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070116/CASEYFAMILYLOGO ) , ...
... , , , , ... food company, today announced the launch of TLC(R) Dark Mocha Almond Chewy ... TLC(R) Chewy Granola Bar family. This new granola bar combines crunchy ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090331/LA91619LOGO ) ...
... /PRNewswire/ - (Ocean Nutrition Canada) - These days, ... purchase dollars, buying products that are local, recycled, ... consumerism is literally changing the world: If given ... products from certified sustainable sources, research from the ...
Cached Medicine News:Health News:Millions in U.S. Can't Afford Health Insurance 2Health News:My InnerView and UW-Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 2Health News:My InnerView and UW-Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 3Health News:NxStage(R) Announces Extension of Medisystems Needle Supply and Distribution Agreement 2Health News:New Report Sets a Course for Improving Foster Care Systems 2Health News:New Report Sets a Course for Improving Foster Care Systems 3Health News:Kashi Company Introduces TLC(R) Dark Mocha Almond Chewy Bar 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 3Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 4Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 5Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 6
Safe. Reliable. Baby-friendly. ,The Hugs infant protection system helps to protect your infants and children from the threat of abduction....
The AeroScout Exciter extends the AeroScout system to provide robust and sophisticated RFID detection capabilities....
... VerdaSee Intelli-Storeroom™ was developed to create ... Room entrances and exits are converted to ... with RFID readers and antennas by VerdaSee's ... are affixed to assets that are to ...
... Aspects provides hospitals with a ... track all their supplies, drugs, ... systems remove all manual compliance ... people accurately. iRIS, or Intelligent ...
Medicine Products: